Factors affecting response variables with emphasis on drug release and loading for optimization of liposomes
Source abstract
Abstract
Drug delivery through Liposomes has shown tremendous potential in terms of the therapeutic application of nanoparticles. There are several drug-loaded liposomal formulations approved for clinical use that help mitigate harmful effects of life-threatening diseases. Developments in the field of liposomal formulations and drug delivery have made it possible for clinicians and researchers to find therapeutic solutions for complicated medical conditions. A key aspect in the development of drug-loaded liposomes is a careful review of optimization techniques to improve the overall formulation stability and efficacy. Optimization studies help in improving/modulating the various properties of drug-loaded liposomes and are vital for the development of this class of delivery systems. A comprehensive overview of the various process variables and factors involved in the optimization of drug-loaded liposomes is presented in this review. The influence of different independent variables on drug release and loading properties with the application of a statistical experimental design is also explained in this article.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Drug Product Technical Services, Wave Life Sciences, MA, USA
References (69)
Show source-provided references
1. 10.4155/tde.10.1310.4155/tde.10.13 ↗
2. 10.1080/21691401.2023.224703610.1080/21691401.2023.2247036 ↗
3. 10.1016/j.jconrel.2013.03.03610.1016/j.jconrel.2013.03.036 ↗
4. Affram K, Udofot O, Cat A, et al. In vitro and in vivo antitumor activity of gemcitabine loaded thermosensitive liposomal nanoparticles and mild hyperthermia in pancreatic cancer. Int J Adv Res. 2015;3(10):859–874.
5. 10.1016/j.colsurfb.2015.09.03410.1016/j.colsurfb.2015.09.034 ↗
6. 10.1016/j.heliyon.2022.e0939410.1016/j.heliyon.2022.e09394 ↗
7. Xu Y, Meng H. Paclitaxel-loaded stealth liposomes: development, characterization, pharmacokinetics and biodistribution, artificial cells. Nanomedicine and Biotechnology. 2014;44:350–355.
8. 10.1158/1535-7163.MCT-15-086710.1158/1535-7163.MCT-15-0867 ↗
9. 10.2174/15672010777931474910.2174/156720107779314749 ↗
10. 10.2147/IJN.S2676610.2147/IJN.S26766 ↗
11. 10.1080/10717544.2016.117713610.1080/10717544.2016.1177136 ↗
12. 10.1186/1556-276X-8-10210.1186/1556-276X-8-102 ↗
13. 10.3390/molecules2704137210.3390/molecules27041372 ↗
14. 10.1155/2011/62923410.1155/2011/629234 ↗
15. 10.1016/j.ijpharm.2019.11891210.1016/j.ijpharm.2019.118912 ↗
16. 10.1248/bpb.b16-0062410.1248/bpb.b16-00624 ↗
17. 10.3389/fchem.2022.88908310.3389/fchem.2022.889083 ↗
18. Zoghi A, Khosravi-Darani K, Omri A. Process variables and design of experiments in liposome and nanoliposome research. Mini-Rev Med Chem. 2016;16(1):16.
19. 10.1155/2016/453579010.1155/2016/4535790 ↗
20. 10.3892/etm.2015.220110.3892/etm.2015.2201 ↗
21. 10.1124/pr.115.01207010.1124/pr.115.012070 ↗
22. 10.1016/j.ijpharm.2016.06.05710.1016/j.ijpharm.2016.06.057 ↗
23. 10.1007/s13346-015-0220-810.1007/s13346-015-0220-8 ↗
24. 10.1080/1071754070160353010.1080/10717540701603530 ↗
25. 10.1016/j.bbamem.2012.10.02210.1016/j.bbamem.2012.10.022 ↗
26. 10.1186/1423-0127-17-5710.1186/1423-0127-17-57 ↗
27. 10.1016/j.ejps.2017.10.03210.1016/j.ejps.2017.10.032 ↗
28. 10.1016/j.jconrel.2017.03.01010.1016/j.jconrel.2017.03.010 ↗
29. 10.1016/j.jddst.2019.10147710.1016/j.jddst.2019.101477 ↗
30. 10.4103/0250-474X.6501410.4103/0250-474X.65014 ↗
31. 10.5402/2012/63674310.5402/2012/636743 ↗
32. 10.1021/acs.molpharmaceut.8b0128410.1021/acs.molpharmaceut.8b01284 ↗
33. 10.1590/s2175-9790201700021612710.1590/s2175-97902017000216127 ↗
34. 10.1080/08982104.2017.134383610.1080/08982104.2017.1343836 ↗
35. 10.1126/science.787142210.1126/science.7871422 ↗
36. 10.3390/pharmaceutics902001210.3390/pharmaceutics9020012 ↗
37. 10.1016/j.colsurfa.2021.12616610.1016/j.colsurfa.2021.126166 ↗
38. Ailiesei I, Anuta V, Mircioiu C, et al. Application of statistical design of experiments for the optimization of clodronate loaded liposomes for oral administration. Rev Chim. 2016;67:1566–1570.
39. 10.2478/afpuc-2019-000910.2478/afpuc-2019-0009 ↗
40. 10.1016/j.bbamem.2006.01.00910.1016/j.bbamem.2006.01.009 ↗
41. 10.1080/0363904070138505510.1080/03639040701385055 ↗
42. 10.7324/JAPS.2015.5070410.7324/JAPS.2015.50704 ↗
43. 10.1016/j.biopha.2018.09.12810.1016/j.biopha.2018.09.128 ↗
44. 10.1016/j.biopha.2018.11.14510.1016/j.biopha.2018.11.145 ↗
45. 10.1016/j.ejpb.2015.06.02610.1016/j.ejpb.2015.06.026 ↗
46. 10.1016/j.colsurfa.2019.12407110.1016/j.colsurfa.2019.124071 ↗
47. 10.3109/21691401.2014.97523810.3109/21691401.2014.975238 ↗
48. 10.3390/molecules2206087010.3390/molecules22060870 ↗
49. 10.2147/IJN.S10503510.2147/IJN.S105035 ↗
50. 10.1016/j.jconrel.2019.10.00410.1016/j.jconrel.2019.10.004 ↗
51. 10.1039/c9ra04814f10.1039/c9ra04814f ↗
52. 10.15761/NDT.100012510.15761/NDT.1000125 ↗
53. 10.2147/DDDT.S12900810.2147/DDDT.S129008 ↗
54. 10.1038/s41598-020-62501-110.1038/s41598-020-62501-1 ↗
55. 10.3109/08982104.2014.99567110.3109/08982104.2014.995671 ↗
56. Sadarani B, Majumdar A, Paradkar S, et al. Enhanced skin permeation of methotrexate from penetration enhancer containing vesicles: in vitro optimization and in vivo evaluation. Biomed Pharmcothe. 2019;114:13.
57. 10.1016/j.ajps.2014.12.00410.1016/j.ajps.2014.12.004 ↗
58. 10.1016/j.ijpharm.2019.11877110.1016/j.ijpharm.2019.118771 ↗
59. 10.1016/j.ijpharm.2007.01.02410.1016/j.ijpharm.2007.01.024 ↗
60. 10.1016/j.chemphyslip.2019.03.01710.1016/j.chemphyslip.2019.03.017 ↗
61. 10.1038/nrd163210.1038/nrd1632 ↗
62. 10.1016/j.addr.2012.09.03710.1016/j.addr.2012.09.037 ↗
63. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
64. 10.3892/mco.2017.125110.3892/mco.2017.1251 ↗
65. Wolfram J, Suri K, Huang Y, et al. Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells. J Microencapsul. 2014:31 (5):501-507.
66. Ahmad H, Arya A, Agrawal S, et al. Chapter 19- Novel lipid nanostructures for delivery of natural agents with antioxidant, anti-inflammatory and antistroke potential: perspectives and outcomes. Micro Nano Technol, 2017;577–605.
67. 10.2147/DDDT.S15676610.2147/DDDT.S156766 ↗
68. 10.1002/jmv.2814410.1002/jmv.28144 ↗
69. 10.1016/j.onano.2023.10013210.1016/j.onano.2023.100132 ↗